Published online before print January 10, 2008

This Article Full Text Full Text (PDF) Supplemental Material All Versions of this Article: ajpath.2008.070858v1 172/2/510    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hirsch, B. Articles by Dürkop, H. Search for Related Content PubMed PubMed Citation Articles by Hirsch, B. Articles by Dürkop, H.

(American Journal of Pathology. 2008;172:510-520.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070858

CD30-Induced Signaling Is Absent in Hodgkin’s Cells but Present in Anaplastic Large Cell Lymphoma Cells

Burkhard Hirsch^*, Michael Hummel^*, Stefan Bentink, Fariba Fouladi^*, Rainer Spang, Raphael Zollinger^*, Harald Stein^* and Horst Dürkop^*

From the Charité-University Medicine Berlin,^*Campus Benjamin Franklin, Institute of Pathology, Berlin, Germany; and the University of Regensburg,Institute of Functional Genomics, Regensburg, Germany

High CD30 expression in classical Hodgkin’s lymphoma and anaplastic large cell lymphoma (ALCL) suggests an important pathogenic role of this cytokine receptor. To test this hypothesis, we investigated CD30 signaling in Hodgkin’s and ALCL cell lines by different approaches: 1) CD30 stimulation, 2) CD30 down-regulation, and 3) a combination of both. The effects were determined at the RNA (microarray and real-time quantitative RT-PCR), protein (electrophoretic mobility shift analysis, immunoblot, and flow cytometry), and cellular/functional (proliferation and apoptosis) levels. We demonstrate that Hodgkin’s cells are virtually CD30 unresponsive. Neither CD30 stimulation nor CD30 silencing of Hodgkin’s cells had any significant effect. In contrast, CD30 stimulation of ALCL cells activated nuclear transcription factor-B (NF-B), induced major transcriptional changes, and decreased proliferation. These effects could be abrogated by down-regulation of CD30. Stimulation of CD30 in ALCL cells, stably transfected with a dominant-negative NF-B inhibitor, induced pronounced caspase activation and massive apoptosis. Our data indicate that 1) CD30 signaling is not effective in Hodgkin’s cell lines but is effective in ALCL cell lines, 2) CD30 is probably not significantly involved in the pathogenesis of classical Hodgkin’s lymphoma, and 3) CD30 stimulation triggers two competing effects in ALCL cells, namely activation of caspases and NF-B-mediated survival. These data suggest that CD30-targeted therapy in ALCL should be combined with NF-B inhibitors to induce effective cell killing.